OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Dr Sabina Heinz, Virology & Liver Diseases Therapy Monitors, Ipsos Healthcare. (T +44 20 3059 5298 E: Sabina.firstname.lastname@example.org)Victoria Allan, Cardiovascular/Respiratory Therapy Monitors, Ipsos Healthcare
The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.